JOP20200157A1 - أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22 - Google Patents

أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22

Info

Publication number
JOP20200157A1
JOP20200157A1 JOP/2020/0157A JOP20200157A JOP20200157A1 JO P20200157 A1 JOP20200157 A1 JO P20200157A1 JO P20200157 A JOP20200157 A JO P20200157A JO P20200157 A1 JOP20200157 A1 JO P20200157A1
Authority
JO
Jordan
Prior art keywords
heavy chain
chain antibodies
antibodies binding
antibodies
compositions
Prior art date
Application number
JOP/2020/0157A
Other languages
English (en)
Inventor
Laura Marie Davison
Shelley Force Aldred
Nathan D Trinklein
Katherine Harris
Udaya Rangaswamy
Heather Anne N Ogana
Schooten Wim Van
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of JOP20200157A1 publication Critical patent/JOP20200157A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن الأجسام المضادة ذات السلسلة الثقيلة لـ CD22 (مثل، UniAbsTM)، بجانب الطرق الخاصة بتصنيع هذه الأجسام المضادة، التركيبات، المتضمنة تركيبات صيدلية، تشتمل على هذه الأجسام المضادة، واستخداماتها لمعالجة اضطرابات الخلية البائية التي يتم تحديد سماتها بواسطة التعبير الوراثي عن CD22.
JOP/2020/0157A 2017-12-22 2018-12-21 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22 JOP20200157A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609759P 2017-12-22 2017-12-22
PCT/US2018/067299 WO2019126756A1 (en) 2017-12-22 2018-12-21 Heavy chain antibodies binding to cd22

Publications (1)

Publication Number Publication Date
JOP20200157A1 true JOP20200157A1 (ar) 2022-10-30

Family

ID=65041936

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0157A JOP20200157A1 (ar) 2017-12-22 2018-12-21 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22

Country Status (21)

Country Link
US (2) US11873336B2 (ar)
EP (1) EP3728319A1 (ar)
JP (2) JP7486421B2 (ar)
KR (1) KR20200104342A (ar)
CN (1) CN111683966B (ar)
AU (1) AU2018392088A1 (ar)
BR (1) BR112020012554A2 (ar)
CA (1) CA3086665A1 (ar)
CL (2) CL2020001703A1 (ar)
CO (1) CO2020008925A2 (ar)
CR (1) CR20200322A (ar)
EA (1) EA202091557A1 (ar)
EC (1) ECSP20042489A (ar)
IL (1) IL275498A (ar)
JO (1) JOP20200157A1 (ar)
MX (1) MX2020006494A (ar)
NI (1) NI202000050A (ar)
PE (1) PE20201171A1 (ar)
PH (1) PH12020550964A1 (ar)
SG (1) SG11202005880XA (ar)
WO (1) WO2019126756A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
CR20190198A (es) 2016-09-14 2019-10-11 Teneobio Inc Anticuerpos de unión a cd3
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
PE20220575A1 (es) * 2019-06-14 2022-04-20 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
KR20210143097A (ko) * 2020-05-19 2021-11-26 (주)이노베이션바이오 Cd22에 특이적인 항체 및 이의 용도
WO2022012682A1 (en) * 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd22 binding molecules and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI2155783T1 (sl) 2007-04-03 2013-10-30 Amgen Research (Munich) Gmbh Medvrstno specifiäśna cd3-epsilon vezavna domena
EP3382022A1 (en) 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
EP2344535A1 (en) 2008-09-19 2011-07-20 MedImmune, LLC Antibodies against sonic hedgehog homolog and uses thereof
HUE030090T2 (en) 2008-10-01 2017-04-28 Amgen Res (Munich) Gmbh Species specific PSMAxCD3 bispecific single chain antibody
EP3141562A1 (en) 2009-03-10 2017-03-15 Biogen MA Inc. Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2501817B2 (en) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Common light chain mouse
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
BR112014025830A8 (pt) 2012-04-20 2017-10-10 Emergent Product Dev Seattle Polipeptídeos de ligação ao cd3
CA2871764A1 (en) 2012-04-26 2013-10-31 Gerhard Frey Anti-cd22 antibodies
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
DK3653049T3 (da) 2012-12-14 2023-11-13 Omniab Inc Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
CN106029098A (zh) * 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
PL3221357T3 (pl) 2014-11-20 2020-11-02 F. Hoffmann-La Roche Ag Wspólne łańcuchy lekkie i sposoby zastosowania
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN104710528B (zh) 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
HUE057220T2 (hu) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
KR20190052006A (ko) * 2016-08-24 2019-05-15 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
CR20190198A (es) 2016-09-14 2019-10-11 Teneobio Inc Anticuerpos de unión a cd3
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
EP4159762A1 (en) 2017-06-30 2023-04-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-b-cell maturation antigen chimeric antigen receptors with human domains
AU2018331421A1 (en) 2017-09-13 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
CN111886250A (zh) 2017-12-27 2020-11-03 特尼奥生物股份有限公司 CD3-δ/ε异二聚体特异性抗体
CN112351997B (zh) 2018-07-20 2023-05-26 坦尼奥第二公司 与cd19结合的重链抗体
KR20210063354A (ko) 2018-09-21 2021-06-01 테네오바이오, 인코포레이티드 이종이량체 다중특이적 항체의 정제 방법
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
MX2021012205A (es) 2019-04-05 2022-02-21 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma.
PE20220575A1 (es) 2019-06-14 2022-04-20 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
EP4077391A1 (en) 2019-12-18 2022-10-26 Teneofour, Inc. Heavy chain antibodies binding to cd38
UY39191A (es) 2020-04-29 2021-11-30 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
WO2021222616A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Methods of treating multiple myeloma
EP4171750A1 (en) 2020-06-30 2023-05-03 Teneobio, Inc. Multi-specific antibodies binding to bcma
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CA3211138A1 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
CN116917327A (zh) 2021-02-26 2023-10-20 特尼奥生物股份有限公司 抗muc1-c抗体及car-t结构
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
KR20230166090A (ko) 2021-04-06 2023-12-06 테네오바이오, 인코포레이티드 항-cd19 항체 및 car-t 구조체
KR20230171952A (ko) 2021-04-16 2023-12-21 테네오바이오, 인코포레이티드 항-cd20 항체 및 car-t 구조
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen

Also Published As

Publication number Publication date
US20210095022A1 (en) 2021-04-01
CL2022002247A1 (es) 2023-02-24
US20240117046A1 (en) 2024-04-11
RU2020124188A (ru) 2022-01-24
PE20201171A1 (es) 2020-10-28
BR112020012554A2 (pt) 2020-11-24
AU2018392088A2 (en) 2020-08-27
SG11202005880XA (en) 2020-07-29
JP2021506325A (ja) 2021-02-22
CO2020008925A2 (es) 2020-10-30
WO2019126756A1 (en) 2019-06-27
EA202091557A1 (ru) 2020-11-18
CR20200322A (es) 2021-01-12
JP7486421B2 (ja) 2024-05-17
CL2020001703A1 (es) 2020-11-06
KR20200104342A (ko) 2020-09-03
EP3728319A1 (en) 2020-10-28
CN111683966B (zh) 2023-07-11
MX2020006494A (es) 2020-11-24
PH12020550964A1 (en) 2021-03-22
AU2018392088A1 (en) 2020-08-13
JP2024062992A (ja) 2024-05-10
IL275498A (en) 2020-08-31
NI202000050A (es) 2020-12-04
CN111683966A (zh) 2020-09-18
CA3086665A1 (en) 2019-06-27
WO2019126756A9 (en) 2019-10-17
ECSP20042489A (es) 2020-11-30
US11873336B2 (en) 2024-01-16

Similar Documents

Publication Publication Date Title
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
JOP20210253A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2019007020A (es) Anticuerpos il-11.
SG10201803042PA (en) Anti-tim-3 antibodies
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
MX2019007021A (es) Anticuerpos il-11ra.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
WO2017091683A8 (en) Antibody molecules to april and uses thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
PH12018500379A1 (en) Biopharmaceutical compositions
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2019014291A (es) Metodo de tratamiento.